Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | NQO2 | P16083 | 4/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1655715 | 0.82 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL20873729 | 0.82 | MCHR1 (0.54) | MCHR1ALDH1A1KDM4E | |
| SCHEMBL27629232 | 0.82 | MCHR1 (0.71) | MCHR1 | |
| SCHEMBL19603062 | 0.82 | MCHR1 (0.67) | MCHR1ALDH1A1PDE10ANQO2PDE3B | |
| SCHEMBL18024109 | 0.81 | NCF1 (0.55) | MCHR1ALDH1A1KDM4E | |
| SCHEMBL15648746 | 0.80 | MCHR1 (0.65) | MCHR1ALDH1A1PDE10ANQO2PDE3B | |
| SCHEMBL873587 | 0.80 | MCHR1 (0.65) | MCHR1ALDH1A1PDE10AKDM4E | |
| SCHEMBL4453824 | 0.79 | KMT2A (0.50) | MCHR1ALDH1A1PDE10AKDM4E | |
| SCHEMBL30886901 | 0.78 | MCHR1 (0.62) | MCHR1ALDH1A1PDE10ANQO2PDE3B | |
| SCHEMBL6690416 | 0.78 | MCHR1 (0.62) | MCHR1ALDH1A1PDE10ANQO2PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105452224-A | Multifunctional quinoline derivatives as anti-neurodegenerative agents | ANNJI PHARM CO LTD | 2016-03-30 | — | — | CN | claimed |
| EP-4363415-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2025-12-10 | — | — | EP | disclosed |
| US-20240279217-A1 | Heterocyclic compounds for the treatment of tuberculosis | TECNIMEDE - Sociedade Técnico-medicinal, SA (PT) | 2024-08-22 | — | — | US | disclosed |
| US-12012394-B2 | Alpha-synuclein ligands | WASHINGTON UNIVERSITY (US) | 2024-06-18 | — | — | US | disclosed |
| EP-4363415-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | Tecnimede, Sociedade Técnico-Medicinal, SA (PT) | 2024-05-08 | — | — | EP | disclosed |
| US-11548867-B2 | Amido compounds as AhR modulators | IDEA YA BIOSCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2023275744-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | TECNIMEDE - Sociedade Técnico-medicinal, SA (PT) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023275744-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | TECNIMEDE - Sociedade Técnico-medicinal, SA (PT) | 2023-01-05 | — | — | WO | disclosed |
| US-20220340875-A1 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS | IDEAYA BIOSCIENCES, INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220158102-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2022-05-19 | — | — | US | disclosed |
| CN-101715453-A | Heterogeneous ring compound and application thereof | AMGEN INC | 2010-05-26 | — | — | CN | disclosed |
| EP-2137186-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009050232-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| CN-101258129-A | Quinoline derivatives and use as antitumor agents | UNIV WAYNE STATE (US) | 2008-09-03 | — | — | CN | disclosed |
| EP-0336544-A1 | Heteroaryl 4-amino-3-acylquinoline derivatives and their use as inhibitors of gastric secretion | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1989-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279217-A1 | Heterocyclic compounds for the treatment of tuberculosis | SDHA, NQO1, FNTB | MCHR1 4778/4885ALDH1A1 568/4885PDE10A 3239/4885 |
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | MCHR1 3453/4885ALDH1A1 3905/4885PDE10A 3271/4885 |
| US-12012394-B2 | Alpha-synuclein ligands | SNCA, PARK7, LRRK2 | MCHR1 551/4885ALDH1A1 2333/4885PDE10A 2028/4885 |
| US-20220158102-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, ODC1, OCIAD2 | MCHR1 3563/4885ALDH1A1 153/4885PDE10A 3952/4885 |
| US-20220340875-A1 | METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS | AHR, MCL1, ARNT | MCHR1 629/4885ALDH1A1 172/4885PDE10A 2669/4885 |
| US-11548867-B2 | Amido compounds as AhR modulators | AHR, ARNT, RXRB | MCHR1 396/4885ALDH1A1 879/4885PDE10A 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.